What is CellCentric?
Founded in 2003 and headquartered in Cambridge, United Kingdom, CellCentric is dedicated to the advancement of a novel drug aimed at treating specific oncological conditions. As a clinical-stage biotechnology company, CellCentric operates within a highly competitive and innovation-driven sector, focusing on translating scientific discoveries into viable treatment options for patients. The company's trajectory suggests a strong emphasis on research and development, moving through critical phases of drug validation and clinical trials to bring its therapeutic candidates to market.
How much funding has CellCentric raised?
CellCentric has raised a total of $424M across 5 funding rounds:
Unspecified
$26M
Unspecified
$33M
Other Financing Round
$25M
Series C
$120M
Series D
$220M
Unspecified (2018): $26M with participation from Morningside Venture Partners
Unspecified (2020): $33M led by Morningside Venture Investments
Other Financing Round (2023): $25M supported by Pfizer
Series C (2025): $120M featuring Forbion, BrightEdge, Avego Healthcare Capital, and RA Capital Management
Series D (2026): $220M backed by Venrock, RA Capital Management, Forbion, Pfizer, BrightEdge - American Cancer Society, Fidelity Investments, Sofinnova Partners, Avego, and HBM Partners
Key Investors in CellCentric
Venrock
Venrock, a venture capital firm founded in 1969, is known for its entrepreneurial support and strategic guidance in technology and healthcare ventures, partnering with founders to build high-growth companies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on public and private healthcare and life science companies, aiming to bring innovations from the lab to the clinic.
Forbion
Forbion is a global life sciences venture capital firm with a strong track record in guiding biotech and biopharmaceutical companies from early stage through clinical development, with a focus on innovative therapeutics.
What's next for CellCentric?
The recent major strategic investment in CellCentric signals a pivotal moment for the company, likely enabling it to accelerate its drug development pipeline, expand its clinical trial operations, and potentially scale its research infrastructure. This substantial capital infusion, particularly in the context of enterprise-level funding, positions CellCentric to navigate the complex and lengthy process of drug commercialization. The company's focus on specific cancers indicates a targeted approach, aiming to address unmet medical needs within oncology. Future developments will likely center on progressing its lead drug candidate through further clinical phases, seeking regulatory approvals, and establishing strategic partnerships for market access.
See full CellCentric company page
